Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

Inclusion Criteria: * Probable mild Alzheimer's disease (MMSE 20-26) or mild cognitive impairment * Increase in total tau or p-tau in CSF * Decrease in amyloid beta in CSF * Stable dose of cholinesterase inhibitors, memantine or selegine or no treatment * Body weight less than 120 kg * Willingness to comply with contraceptive methods if self or partner is of child-bearing potential Exclusion Criteria: * Any other cause of dementia * Other significant neurologic or psychiatric illness * Hachinski Ischemia Score \>4 * More than 3 microbleeds on MRI * Type 2 diabetes not controlled by diet * Risk of cerebrovascular disease, cerebral haemorrhage or stroke * History of systemic autoimmune disease * Use of platelet anti-aggregates or anti-coagulants (Aspirin up to 325 mg/day is allowable) * Use of chronic corticosteroids * Uncontrolled hypertension in spite of antihypertensive medications * Renal or hepatic insufficiency or clinically significant anaemia * In nursing home care * Contraindications to lumbar puncture or MRI * Prior participation in therapeutic studies only after adequate wash-out period